{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:33:12Z","timestamp":1793403192460,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["22-076"],"award-info":[{"award-number":["22-076"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.neuropharm.2025.110762","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:48:59Z","timestamp":1762328939000},"page":"110762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["LSD microdosing in major depressive disorder: results from an open-label trial"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-2873","authenticated-orcid":false,"given":"Dimitri","family":"Daldegan-Bueno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6936-4587","authenticated-orcid":false,"given":"Carina Joy","family":"Donegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2652-4617","authenticated-orcid":false,"given":"Rachael","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Alshakhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4833-2333","authenticated-orcid":false,"given":"Rhys","family":"Ponton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partha","family":"Roop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hoeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Sundram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-7896","authenticated-orcid":false,"given":"David","family":"Menkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Muthukumaraswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neuropharm.2025.110762_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110762_bib2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","article-title":"Acute subjective and behavioral effects of microdoses of Lysergic acid diethylamide in healthy human volunteers","volume":"86","author":"Bershad","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110762_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/156802610791111524","article-title":"Emerging opportunities and concerns for drug discovery at Serotonin 5-5-HT2B receptors","volume":"10","author":"Brea","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110762_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2024.106669","article-title":"Classical psychedelics' action on brain monoaminergic systems","volume":"176","author":"Butler","year":"2024","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110762_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an understanding of psychedelic-induced neuroplasticity","volume":"48","author":"Calder","year":"2023","journal-title":"Neuropsychopharmacology : Off. Pub. Am. College Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110762_bib6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s13063-024-08384-3","article-title":"LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder","volume":"25","author":"Daldegan-Bueno","year":"2024","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110762_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s40814-023-01399-8","article-title":"An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)","volume":"9","author":"Donegan","year":"2023","journal-title":"Pilot Feasib. Stud."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110762_bib8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers","volume":"237","author":"Family","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110762_bib9","article-title":"Psychedelic drugs: considerations for clinical investigations. (FDA-2023-D-1987)","year":"2023","journal-title":"Food Drug Admin."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110762_bib10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S2215-0366(16)30307-8","article-title":"Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies","volume":"3","author":"Furukawa","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110762_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110762_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/02698811231211219","article-title":"Drug\u2013drug interactions involving classic psychedelics: a systematic review","volume":"38","author":"Halman","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110762_bib13","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1007\/s00213-022-06249-8","article-title":"Set and setting in microdosing: an oft-overlooked principle","volume":"239","author":"Hartogsohn","year":"2022","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110762_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S2215-0366(24)00133-0","article-title":"Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis","volume":"11","author":"Henssler","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110762_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110762_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/cpt.2057","article-title":"Pharmacokinetics and pharmacodynamics of Lysergic acid diethylamide microdoses in healthy participants","volume":"109","author":"Holze","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110762_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/pst.185","article-title":"Sample size of 12 per group rule of thumb for a pilot study","volume":"4","author":"Julious","year":"2005","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.neuropharm.2025.110762_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jad.2022.09.168","article-title":"Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis","volume":"322","author":"Ko","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110762_bib19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110762_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/02791072.2019.1683260","article-title":"Psychedelic microdosing: a subreddit analysis","volume":"52","author":"Lea","year":"2020","journal-title":"J. Psychoact. Drugs"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110762_bib21","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00213-020-05477-0","article-title":"Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders","volume":"237","author":"Lea","year":"2020","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110762_bib22","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s11136-019-02177-x","article-title":"Systematic review of the measurement properties of the depression anxiety stress Scales\u201321 by applying updated COSMIN methodology","volume":"28","author":"Lee","year":"2019","journal-title":"Qual. Life Res."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110762_bib23","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110762_bib24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","article-title":"The Hamilton anxiety scale: reliability, validity and sensitivity to change in anxiety and depressive disorders","volume":"14","author":"Maier","year":"1988","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110762_bib26","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41386-023-01772-4","article-title":"Greater subjective effects of a low dose of LSD in participants with depressed mood","volume":"49","author":"Molla","year":"2024","journal-title":"Neuropsychopharmacology : Off. Pub. Am. College Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110762_bib27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110762_bib28","article-title":"Microdosing psychedelics: current evidence from controlled studies","author":"Murphy","year":"2024","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110762_bib29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","article-title":"Acute mood-elevating properties of microdosed Lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial","volume":"94","author":"Murphy","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110762_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.forsciint.2018.01.006","article-title":"Is LSD toxic?","volume":"284","author":"Nichols","year":"2018","journal-title":"Forensic Sci. Int."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110762_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1037\/0022-3514.61.1.115","article-title":"A prospective study of depression and posttraumatic stress symptoms after a natural disaster: the 1989 Loma Prieta Earthquake","volume":"61","author":"Nolen-Hoeksema","year":"1991","journal-title":"J. Personality Soc. Psychol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110762_bib32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/0192623317690609","article-title":"Regulatory Forum review\u2217: utility of in vitro secondary pharmacology data to assess risk of drug-induced valvular heart disease in humans: Regulatory considerations","volume":"45","author":"Papoian","year":"2017","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.neuropharm.2025.110762_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104706","article-title":"The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955\u20132021) and recommendations for the field","volume":"139","author":"Polito","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110762_bib34","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110762_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1037\/cps0000110","article-title":"Rumination across depression, anxiety, and eating disorders in adults: a meta-analytic review","volume":"31","author":"Rickerby","year":"2024","journal-title":"Clin. Psychol. Sci. Pract."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2025.110762_bib36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2015.07.062","article-title":"Development and validation of the dimensional Anhedonia rating scale (DARS) in a community sample and individuals with major depression","volume":"229","author":"Rizvi","year":"2015","journal-title":"Psychiatry Res."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110762_bib37","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/0269881120919957","article-title":"Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis","volume":"34","author":"Romeo","year":"2020","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110762_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","article-title":"Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial","volume":"44","author":"Rosenbaum","year":"1998","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110762_bib39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/B:QURE.0000018486.91360.00","article-title":"The world health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group","volume":"13","author":"Skevington","year":"2004","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.neuropharm.2025.110762_bib40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1192\/bjp.148.5.599","article-title":"Grade scores of the montgomery-asberg depression and the clinical anxiety scales","volume":"148","author":"Snaith","year":"1986","journal-title":"Br. J. Psychiatry"},{"issue":"13","key":"10.1016\/j.neuropharm.2025.110762_bib41","first-page":"23","article-title":"When at first you don't succeed: sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110762_bib42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S2215-0366(14)00092-3","article-title":"Placebo eff ects in psychiatry: mediators and moderators","volume":"2","author":"Weimer","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110762_bib43","series-title":"Depressive Disorder (Depression)","year":"2023"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110762_bib44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery Asberg depression rating scale (SIGMA)","volume":"192","author":"Williams","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110762_bib45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jocn.2020.08.013","article-title":"Application of antidepressants in depression: a systematic review and meta-analysis","volume":"80","author":"Yuan","year":"2020","journal-title":"J. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110762_bib46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4088\/JCP.v65n0204","article-title":"Defining remission on the montgomery-asberg depression rating scale","volume":"65","author":"Zimmerman","year":"2004","journal-title":"J. Clin. Psychiatry"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:19:43Z","timestamp":1780820383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":45,"alternative-id":["S0028390825004708"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110762","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LSD microdosing in major depressive disorder: results from an open-label trial","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110762"}}